Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE studies of renal function-based pemetrexed dosing
NL-OMON54624Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) and mesothelioma (4 arms), sponsored by Radboud University Medical Center. Started Feb 2019; status: recruiting.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on NL-OMON54624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54624.